Skip to main content
Equibles
APUS logo

APUS · Apimeds Pharmaceuticals US, Inc.

Track APUS — free

Use APUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.80 +0.13 (+7.78%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$2.47M
Shares
1.51M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.67 Open$1.73 Day$1.60–1.92 Since split$1.60–30.00 Avg vol 30d123K Short int20K · 1.3% float · 1.0d Short vol23% DataMar 2026–Sep 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Mar 26, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Mar 26, 2026.

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$58.17M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+65.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.3%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −64%
below
RSI (14) 22
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+17% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.32% of float · ▲ +33.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
7 holders — mid 1-yr range
Squeeze score 35
low risk · 0–100
Fundamentals
Poor
EPS growth −206%
Y/Y
Free cash flow $-9.0M
Quant / Vol
risk profile
Very High
Volatility 174%
annualized · 1-yr
Max drawdown −95%
past year
ATR 32.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−64% Bearish
RSI (14)
22 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+17% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.32% of float · ▲ +33.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
7 holders — mid 1-yr range
Price context
position in its range since split · 2026-03-26
Range low $2 Now $2 · 0% Range high $30
vs 50-day avg -64%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
APUS
Apimeds Pharmaceuticals US, Inc.
this stock
$2.47M — — — 1.3%
TAK
Takeda Pharmaceutical Co Ltd
 $59.80B +22.2% — — 0.1%
TEVA
Teva Pharmaceutical Industries Ltd
 $45.49B +25.6% +4.3% 64.0 3.2%
GALDY
Galderma Group AG/ADR
 $44.48B -8.0% — — 0.0%
HLN
Haleon plc
 $41.16B -7.4% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
7
% held
2.8%
Net QoQ
-2.2K sh
Top holder
Hemenway Trust Co LLC
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
19.9K
Days to cover
1.0d
Change
+5.0K sh
View
Short Volume
Short vol %
23%
As of
Sep 17, 2026
Short Total
View
Fails to Deliver
FTD shares
3.0K
Value
$11.7K
As of
Aug 28, 2026
View
Off-Exchange
Off-exchange %
9.8%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-6.0M
EPS diluted
$-5.50
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 11, 2026
This year
17
View

Performance

Raw-price comparisons begin at the captured split on Mar 26, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
APUS -23.0% -62.0% — -57.0% —
SPY +0.6% -0.8% +18.2% -0.6% +11.8%
vs SPY -23.7% -61.1% — -56.4% —
Key facts CIK 1894525 CUSIP 03771D201 Visit website